WSPH Patent News ...
Tuesday July 31, 1:57 pm Eastern Time
Press Release
Wasatch Pharmaceutical Inc. Announces Five Usage Patents Filed July 27, 2001, for Treatment of Various Skin Disorders
MURRAY, Utah--(BUSINESS WIRE)--July 31, 2001--(OTCBB:WSPH - news) Gary Heesch, president and CEO of Wasatch Pharmaceutical Inc., announced that on July 27, 2001, the company filed for patents on FDA prescription drugs with five applications for use in the treatment of various skin disorders, including difficult to heal wounds.
Antidotal studies have produced dramatic results with patients having a compromised immune system often associated with diabetics, cancer patients and other physiological deficiencies. These results justify additional clinical trials that should be concluded by February 2002.
The use of this medication on diabetics and cancer patients receiving chemotherapy and/or radiation therapy has demonstrated accelerated normal healing and the prevention of amputation in the case of diabetics. The preliminary scabbing of sores thus far has been accomplished within 24 hours and complete healing comparable to normal healing times of healthy individuals.
Wasatch Pharmaceutical is preparing marketing strategies in anticipation of successful clinical trials to be conducted in the next six months. This will be a direct sales approach to physicians and hospitals and eventually will be made available to physicians throughout the world through our Internet exposure. The need for this product is wide spread, and the projected $100 million plus U.S. market is expected to respond positively to the significant benefits provided by the Wasatch product. The characteristics of this therapy are such that penetration of the U.S. market should be expeditious, provide significant revenues for Wasatch and become the therapy of choice for the treatment of difficult to heal wounds.
As indicated in a previous press release, the company will feature each of the five usage patents on a weekly basis to give them maximum exposure and the attention they deserve.
For additional information about Wasatch Pharmaceutical, please review our Web sites: www.wasatchpharm.com and www.restoremyskin.com.
Forward-looking statements in this release are made pursuant to the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the company's products, increased levels of competition, new products introduced by competitors, changes in the rates of subscriber acquisition and retention and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact:
Equitilink LLC, Murray
Ronald L. Garner, 877/788-1940
Fax: 858/824-0452
E-mail: ron@equitilinkpr.com
www.wasatchpharm.com
www.restoremyskin.com
biz.yahoo.com |
